Drug Information Association Logo
Corporate Tagline

14th Eudravigilance Information Day

May 23 2013 8:45AM - May 23 2013 5:00PM | European Medicines Agency Canary Wharf, 7 Westferry Circus London E14 4HB United Kingdom

« Back to Listing

Overview 

Need for this EudraVigilance Information Day

EudraVigilance Information Days provide a forum to update stakeholders about the achievements and latest developments with regard to the implementation of the new pharmacovigilance legislation. It will provide important technical and operational details that need to be taken into account by marketing authorisation holders in their daily application of the new legislation in the broader context of EudraVigilance and adverse reaction reporting in the EU.

This EudraVigilance Information Day will highlight the latest developments in applying data privacy legislation and the impact on adverse drug reaction data exchange between stakeholders. A dedicated questions and answers session will focus on expected updates of the Good Pharmacovigilance Practice (GVP) Module VI, relating to the management and reporting of adverse reactions to medicinal products. Other topics will include highlights of the work of the new Pharmacovigilance and Risk Assessment Committee (PRAC), including experience on signal management related to electronic reaction monitoring reports (eRMRs) and based on EudraVigilance data, practical experience with the new Pharmacovigilance System Master File (PSMF) and updates on the Risk Management Plan, including the latest information on Post-Authorisation Safety Studies (PASS) and Post-Authorisation Efficacy Studies (PAES).

A look at the pharmacovigilance activities of the Croatian Medicines Agency (HALMED) in preparation for EU accession on 1 July 2013 will conclude this Information Day.

Who Should Attend 

This programme will benefit Qualified Persons Responsible for Pharmacovigilance (QPPVs) and individuals involved in:

  • Pharmacovigilance
  • Clinical Development
  • Information Management
  • Safety databases

Featured Topics 

  • Latest developments on applying data privacy legislation and its impact on the adverse drug reaction data exchange between stakeholders
  • Update of GVP Module VI – detailed questions and answers session
  • Medicinal products subject to additional monitoring
  • The work of the PRAC
  • Experience of signal management based on EudraVigilance data
  • Implementation experience with the new PSMF
  • Risk Management Planning including the latest information on PASS and PAES
  • EU accession of Croatia

Contact Information 

Registration and Agenda:
DIA Europe
Kuechengasse 16, Postfach
4002 Basel, Switzerland
Phone: +41 61 225 51 51
Fax: +41 61 225 51 52
E-mail: diaeurope@diaeurope.org

For technical questions or registration to EudraVigilance:
Eudravigilance helpdesk for Sponsors:
eudravigilance@ema.europa.eu
EudraVigilance registration team:
eudravigilanceregistration@ema.europa.eu

Hotel & Travel 

HOTEL INFORMATION
Attendees have to make their own reservation. Recommended hotel close to the EMA:


Hilton London Docklands Riverside
265 Rotherhithe Street,
London , SE16 5HW,
United Kingdom

Telephone: +44 (0)20 7231 1001
Fax: +44 (0)20 7231 0599
Email: reservations.docklands@hilton.com

Britannia International
Marsh Wall,
London, E14 9SJ,
United Kingdom
Telephone: +44 (0)871 222 0042
Fax: +44 (0) 871 222 7712

Faculty 

Previous Next

Agenda  

Day 1 Thursday, May 23, 2013

  • 9:00AM - 10:30AM

    The work of the Pharmacovigilance Risk Assessment Committee (PRAC) and signal management experience based on EudraVigilance data

    This session will provide an important overview of the composition, the mandate and the output of the PRAC. In addition, the experience on signal management based on the Guideline on good pharmacovigilance practices (GVP), module IX “Signal management” as well as the use of the electronic reaction monitoring reports (eRMRs) generated from EudraVigilance data will be presented from a Member State and EMA perspective.

    Speaker(s):

    • The work of Pharmacovigilance Risk Assessment Committee (PRAC): Assessment and monitoring of safety issues
      Almath Spooner
      Pharmacovigilance and Risk Management Lead, IMB and Vice Chair, PRAC
      IMB, Ireland
    • Signal management activities by the Medicines Evaluation Board (MEB)
      Sabine Straus, MD
      Head of Pharmacovigilance
      Medicines Evaluation Board, Netherlands
    • Signal management activities by the EMA
      Georgy Genov, MD
      Head of Signal Detection and Data Analysis
      European Medicines Agency, European Union, United Kingdom
  • 11:00AM - 11:40AM

    EU accession of Croatia

    In preparation of the EU accession on 1 July 2013, this session will give a unique insight of the pharmacovigilance activities of the Croatian Agency for Medicinal Products and Medical Devices (Agencija zalijekove i medicinske proizvode, HALMED). More specifically, aspects of electronic adverse reaction reporting and the plans for electronic submission of information on medicines will be addressed

    Speaker(s):

    • EU accession of Croatia
      Viola Macolic Sarinic, MD,MSc
      Head of Department of Pharmacovigilance, Drug Consumption
      Agency For Medicinal Products & Med. Devices (HALMED), Croatia (Hrvatska)
    • EU accession of Croatia
      Nenad Cajko
      Associate for IT Affairs
      HALMED, Croatia (Hrvatska)
  • 11:40AM - 12:30PM

    Implementation experience with the new Pharmacovigilance System Master File (PSMF)

    The legal requirement for marketing authorisation holders to maintain and make available upon request a Pharmacovigilance System Master File (PSMF) was introduced to harmonise and strengthen the conduct of pharmacovigilance activities in the EU. This session will provide the opportunity to hear from the Federal Institute for Drugs and Medical Devices (BfArM) Pharmacovigilance Inspectorate about the initial implementation experience and to discuss frequently asked questions in the context of the PSMF.

    Speaker(s):

    • Experience with the PSMF from a pharmacovigilance inspection perspective
      Kimberley Sherwood
      Pharmacovigilance Inspector
      Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Germany
    • Frequently asked questions and answers related to the PSMF
      Sophia Mylona
      Scientific Administrator, Inspection Sector
      European Medicines Agency, United Kingdom
  • 1:30PM - 3:00PM

    Guideline on good pharmacovigilance practices: Update of Module VI – Management and reporting of adverse reactions, data privacy and coding with MedDRA

    This session will provide an update on the requirements on adverse reaction reporting applicable to post-authorisation studies and will allow for the discussion of frequently asked questions in relation to the practical application of GVP module VI. Furthermore, highlights of the EU data privacy legislation in the context of adverse reaction reporting and EudraVigilance will be presented. In addition, an update on MedDRA coding aspects related to the new pharmacovigilance legislation will be provided.

    Speaker(s):

    • Updated requirements on reporting for post-authorisation studies and questions and answers
      Gilles Touraille
      European Medicines Agency, United Kingdom
    • Updated requirements on reporting for post-authorisation studies and questions and answers
      Mick Foy
      Group Manager
      MHRA, United Kingdom
    • Data privacy legislation and impact on the adverse drug reaction data exchange between stakeholders and EudraVigilance
      Alessandro Spina
      European Medicines Agency, United Kingdom
    • MedDRA Term Selection: Latest activities of the Points to Consider Working Group
      Patrick Revelle
      Director
      MedDRA MSSO , United States
  • 3:30PM - 4:30PM

    Risk Management Plan including the latest information on Post -Authorisation Safety Studies (PASS) and Post - Authorisation Efficacy Studies (PAES) and latest developments on medicinal products subject to additional monitoring

    Speaker(s):

    • Risk Management Plan including the latest information on Post-Authorisation Safety Studies (PASS) and Post-Authorisation Efficacy Studies (PAES)
      Xavier Kurz, MD
      European Medicines Agency, European Union, United Kingdom
    • Latest developments on medicinal products subject to additional monitoring
      Ana Hidalgo-Simon
      Head of Signal Detection and Data Analysis
      European Medicines Agency, United Kingdom

Registration Fees 

Other Fees

Academia
€180.00
Government (Full Time)
€150.00
Industry
€365.00
Register Online
« Back to Listing Back To Top